BCL11A is a Triple-negative breast cancer gene with critical functions in stem and progenitor cells

Nature Communications

Volumn 6, Issue , 2015, Pages

  Khaled, Walid T ^a,b   Lee, Song Choon ^a   Stingl, John ^b   Chen, Xiongfeng ^c   Ali, H Raza ^b,d   Rueda, Oscar M ^b   Hadi, Fazal ^b   Wang, Juexuan ^a   Yu, Yong ^a   Chin, Suet Feung ^b   Stratton, Mike ^a   Futreal, Andy ^a   Jenkins, Nancy A ^e   Aparicio, Sam ^f   Copeland, Neal G ^e   Watson, Christine J ^b   Caldas, Carlos ^b,d,g   Liu, Pentao ^a  

^a WELLCOME TRUST SANGER INSTITUTE   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c SAIC FREDERICK INC   (United States)

^d Cambridge Experimental Cancer Medicine Centre   (United Kingdom)

^e HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^f BRITISH COLUMBIA CANCER AGENCY   (Canada)

^g ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR BCL 2A; UNCLASSIFIED DRUG; 7,12 DIMETHYLBENZ[A]ANTHRACENE; BCL11A PROTEIN, HUMAN; BCL11A PROTEIN, MOUSE; CARRIER PROTEIN; NUCLEAR PROTEIN;

CANCER; CELLS AND CELL COMPONENTS; ENDOCRINE SYSTEM; GENE; GENE EXPRESSION; MOLECULAR ANALYSIS; NUMERICAL MODEL; PATHOLOGY; TUMOR; WOMENS HEALTH;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER CELL LINE; BREAST EPITHELIUM CELL; CANCER REGRESSION; CARCINOGENESIS; CARCINOGENICITY; CONTROLLED STUDY; FEMALE; GENE LOCUS; GENE OVEREXPRESSION; GENOMICS; HEMATOPOIESIS; MOUSE; NONHUMAN; ONCOGENE; PROTEIN EXPRESSION; STEM CELL; TRIPLE NEGATIVE BREAST CANCER; TUMOR GENE; TUMOR XENOGRAFT; ANIMAL; CANCER TRANSPLANTATION; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DNA MICROARRAY; GENE EXPRESSION REGULATION; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; PROGNOSIS; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR CELL LINE; UDDER;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ANIMALS; CARRIER PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MAMMARY GLANDS, ANIMAL; MICE; NEOPLASM TRANSPLANTATION; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; STEM CELLS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84986587041     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms6987     Document Type: Article

References (60)

1. Blows, F. M. et al. Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10, 159 cases from 12 studies. PLoS Med. 7, e1000279 (2010).
2. Foulkes, W. D., Smith, I. E. & Reis-Filho, J. S. Triple-negative breast cancer. N. Engl. J. Med. 363, 1938-1948 (2011).
3. Perou, C. M. et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
4. Carey, L., Winer, E., Viale, G., Cameron, D. & Gianni, L. Triple-negative breast cancer: disease entity or title of convenience? Nat. Rev. Clin. Oncol. 7, 683-692 (2010).
5. Curtis, C. et al. The genomic and transcriptomic architecture of 2, 000 breast tumours reveals novel subgroups. Nature 486, 346-352 (2012).
6. Prat, A. et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 12, R68 (2010).
7. Weigelt, B., Baehner, F. L. & Reis-Filho, J. S. The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade. J. Pathol. 220, 263-280 (2010).
8. TCGA. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
9. Shah, S. P. et al. The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486, 395-399 (2012).
10. Stingl, J. & Caldas, C. Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis. Nat. Rev. Cancer 7, 791-799 (2007).
11. Bouras, T. et al. Notch signaling regulates mammary stem cell function and luminal cell-fate commitment. Cell Stem Cell 3, 429-441 (2008).
12. Kouros-Mehr, H., Slorach, E. M., Sternlicht, M. D. & Werb, Z. GATA-3 maintains the differentiation of the luminal cell fate in the mammary gland. Cell 127, 1041-1055 (2006).
13. Asselin-Labat, M. L. et al. Gata-3 is an essential regulator of mammary-gland morphogenesis and luminal-cell differentiation. Nat. Cell Biol. 9, 201-209 (2007).
14. Khaled, W. T. et al. The IL-4/IL-13/Stat6 signalling pathway promotes luminal mammary epithelial cell development. Development 134, 2739-2750 (2007).
15. Zuo, T. et al. FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 129, 1275-1286 (2007).
16. Mehra, R. et al. Identification of GATA3 as a breast cancer prognostic marker by global gene expression meta-analysis. Cancer Res. 65, 11259-11264 (2005).
17. Desmedt, C. et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin. Cancer Res. 13, 3207-3214 (2007).
18. Hatzis, C. et al. A genomic predictor of response and survival following taxaneanthracycline chemotherapy for invasive breast cancer. JAMA 305, 1873-1881 (2011).
19. Ma, X. J. et al. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 5, 607-616 (2004).
20. Schmidt, M. et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res. 68, 5405-5413 (2008).
21. Weniger, M. A. et al. Gains of the proto-oncogene BCL11A and nuclear accumulation of BCL11A (XL) protein are frequent in primary mediastinal B-cell lymphoma. Leukemia. 20, 1880-1882 (2006).
22. Nakamura, T. et al. Evi9 encodes a novel zinc finger protein that physically interacts with BCL6, a known human B-cell proto-oncogene product. Mol. Cell Biol. 20, 3178-3186 (2000).
23. Reichmann, E., Ball, R., Groner, B. & Friis, R. R. New mammary epithelial and fibroblastic cell clones in coculture form structures competent to differentiate functionally. J. Cell Biol. 108, 1127-1138 (1989).
24. Ince, T. A. et al. Transformation of different human breast epithelial cell types leads to distinct tumor phenotypes. Cancer Cell 12, 160-170 (2007).
25. Elenbaas, B. et al. Human breast cancer cells generated by oncogenic transformation of primary mammary epithelial cells. Genes Dev. 15, 50-65 (2001).
26. Ishikawa, F. et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain (null) mice. Blood 106, 1565-1573 (2005).
27. Liu, P. et al. Bcl11a is essential for normal lymphoid development. Nat. Immunol. 4, 525-532 (2003).
28. Herschkowitz, J. I. et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 8, R76 (2007).
29. Herschkowitz, J. I. et al. Comparative oncogenomics identifies breast tumors enriched in functional tumor-initiating cells. Proc. Natl Acad. Sci. USA 109, 2778-2783 (2012).
30. Jonkers, J. et al. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 29, 418-425 (2001).
31. Hennighausen, L. & Robinson, G. W. Information networks in the mammary gland. Nat. Rev. Mol. Cell Biol. 6, 715-725 (2005).
32. Stingl, J. et al. Purification and unique properties of mammary epithelial stem cells. Nature 439, 993-997 (2006).
33. Shackleton, M. et al. Generation of a functional mammary gland from a single stem cell. Nature 439, 84-88 (2006).
34. Lim, E. et al. Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res. 12, R21 (2010).
35. Van Keymeulen, A. et al. Distinct stem cells contribute to mammary gland development and maintenance. Nature 479, 189-193 (2011).
36. Rios, A. C., Fu, N. Y., Lindeman, G. J. & Visvader, J. E. In situ identification of bipotent stem cells in the mammary gland. Nature 506, 322-327 (2014).
37. Lim, E. et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat. Med. 15, 907-913 (2009).
38. Molyneux, G. et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell 7, 403-417 (2010).
39. Zhou, D., Liu, K., Sun, C. W., Pawlik, K. M. & Townes, T. M. KLF1 regulates BCL11A expression and gamma- to beta-globin gene switching. Nat. Genet. 42, 742-744 (2010).
40. Jiang, B. Y. et al. BCL11A overexpression predicts survival and relapse in nonsmall cell lung cancer and is modulated by microRNA-30a and gene amplification. Mol. Cancer 12, 61 (2013).
41. Senawong, T., Peterson, V. J. & Leid, M. BCL11A-dependent recruitment of SIRT1 to a promoter template in mammalian cells results in histone deacetylation and transcriptional repression. Arch. Biochem. Biophys. 434, 316-325 (2005).
42. Yin, B. et al. A retroviral mutagenesis screen reveals strong cooperation between Bcl11a overexpression and loss of the Nf1 tumor suppressor gene. Blood 113, 1075-1085 (2008).
43. Yu, Y. et al. Bcl11a is essential for lymphoid development and negatively regulates p53. J. Exp. Med. 209, 2467-2483 (2012).
44. Chan, W. et al. A recombineering based approach for high-throughput conditional knockout targeting vector construction. Nucleic Acids Res. 35, e64 (2007).
45. Liu, P., Jenkins, N. A. & Copeland, N. G. A highly efficient recombineeringbased method for generating conditional knockout mutations. Genome Res. 13, 476-484 (2003).
46. Hameyer, D. et al. Toxicity of ligand-dependent Cre recombinases and generation of a conditional Cre deleter mouse allowing mosaic recombination in peripheral tissues. Physiol. Genomics 31, 32-41 (2007).
47. Dontu, G. et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 17, 1253-1270 (2003).
48. Moffat, J. et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124, 1283-1298 (2006).
49. Wang, X. & Seed, B. A PCR primer bank for quantitative gene expression analysis. Nucleic Acids Res. 31, e154 (2003).
50. Bengtsson, H., Wirapati, P. & Speed, T. P. A single-array preprocessing method for estimating full-resolution raw copy numbers from all Affymetrix genotyping arrays including GenomeWideSNP 5 & 6. Bioinformatics 25, 2149-2156 (2009).
51. Venkatraman, E. S. & Olshen, A. B. A faster circular binary segmentation algorithm for the analysis of array CGH data. Bioinformatics 23, 657-663 (2007).
52. Seshan VE, O. A. DNAcopy: DNA copy number data analysis R package http://www.bioconductor.org/packages/2.3/bioc/html/DNAcopy.html (2010).
53. Dunning, M. J., Smith, M. L., Ritchie, M. E. & Tavare, S. beadarray: R classes and methods for Illumina bead-based data. Bioinformatics 23, 2183-2184 (2007).
54. Cairns, J. M., Dunning, M. J., Ritchie, M. E., Russell, R. & Lynch, A. G. BASH: a tool for managing BeadArray spatial artefacts. Bioinformatics 24, 2921-2922 (2008).
55. Barbosa-Morais, N. L. et al. A re-annotation pipeline for Illumina BeadArrays: improving the interpretation of gene expression data. Nucleic Acids Res. 38, e17.
56. Parker, J. S. et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J. Clin. Oncol. 27, 1160-1167 (2009).
57. Yeung, K. Y., Fraley, C., Murua, A., Raftery, A. E. & Ruzzo, W. L. Model-based clustering and data transformations for gene expression data. Bioinformatics 17, 977-987 (2001).
58. Fraley, C. & Raftery, A. E. MCLUST Version 3 for R: Normal Mixture Modeling and Model-based Clustering. Technical Report No. 504, Department of Statistics, University of Washington (2006).
59. Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401-404 (2012).
60. Kononen, J. et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat. Med. 4, 844-847 (1998).